Survival trends in the era of novel therapies identify unmet needs in peripheral T-cell lymphoma: a national cancer database analysis - Report - MDSpire
Advertisement
Survival trends in the era of novel therapies identify unmet needs in peripheral T-cell lymphoma: a national cancer database analysis
Trends in Survival Rates with New Treatments in Peripheral T-Cell Lymphoma
Overview
This analysis of the National Cancer Database reveals improved overall survival (OS) rates for patients with peripheral T-cell lymphoma (PTCL) following the introduction of novel therapies. Notably, patients diagnosed in the era of new treatments (2012-2020) exhibited significantly better OS compared to those diagnosed earlier (2004-2011).
Background
Peripheral T-cell lymphomas (PTCL) represent a diverse group of aggressive lymphoproliferative disorders, accounting for approximately 10% of non-Hodgkin lymphomas. Historically, treatment options have been limited, and outcomes have been poor, necessitating the exploration of new therapeutic agents. Understanding the impact of these new treatments on survival outcomes is crucial for optimizing patient management and addressing unmet clinical needs.
Data Highlights
{'format': 'table', 'content': [{'Era': 'Era 1 (2004–2011)', 'Median OS (months)': 15.5, '3-Year OS Rate': '38.3%', '5-Year OS Rate': '31.8%'}, {'Era': 'Era 2 (2012–2020)', 'Median OS (months)': 18.5, '3-Year OS Rate': '40.0%', '5-Year OS Rate': '33.5%'}]}
Key Findings
Patients diagnosed with PTCL-NOS or AITL in Era 2 had a median OS of 18.5 months compared to 15.5 months in Era 1.
For ALCL patients, the median OS improved from 65.5 months in Era 1 to 114.5 months in Era 2.
The 3-year OS rate for ALCL increased from 55.1% in Era 1 to 65.6% in Era 2.
Multivariate analysis indicated that diagnosis in Era 2 was associated with a lower risk of death (HR = 0.930).
Factors such as increased age, male sex, and higher comorbidity scores were linked to higher mortality rates.
Patients in Era 2 were more likely to present with advanced disease stages and receive treatment at academic centers.
Clinical Implications
The findings underscore the importance of incorporating novel therapies into treatment regimens for PTCL, particularly for improving survival outcomes. Clinicians should remain vigilant about the evolving landscape of PTCL treatments and consider patient characteristics when making therapeutic decisions.
Conclusion
The introduction of new therapies has significantly improved survival rates in patients with PTCL, highlighting the need for ongoing research and adaptation of treatment strategies to address the complexities of this disease.
by Julia Wang, Yajuan Gao, N. Nora Bennani, Yun Kyoung Tiger, Arushi Khurana, Urshila Durani, Jonas Paludo, Gita Thanarajasingam, Steven R. Hwang, Yucai Wang, Grzegorz S. Nowakowski, Thomas M. Habermann, Thomas E. Witzig, Stephen M. Ansell, Jithma P. Abeykoon
